P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1 p
12. okt, 09:49:20 GMT +8 · SGD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse P8A põhistatistika genereerimine…
Turu kapit.
32,37 mln
Keskm. maht
1,32 tuh
Maht
0,00
52 näd kõrgeim
0,26 SGD
52 näd madalaim
0,10 SGD
Aktsiatulu
−0,04 SGD
Käibivad aktsiad
267,53 mln
Töötajate arv
111
Turu kapit.
32,37 mln
Keskm. maht
1,32 tuh
Maht
0,00
52 näd kõrgeim
0,26 SGD
52 näd madalaim
0,10 SGD
Aktsiatulu
−0,04 SGD
Käibivad aktsiad
267,53 mln
Töötajate arv
111
Uudised
Veebiallikatest ja uudistepartneritelt
Simply Wall Street
·
31 minuti eest
Freshworks (FRSH) Shares Just Moved, So What Is Going On?
KuCoin
·
21 minuti eest
Nasdaq posts its worst weekly decline since June, gold rebounds but faces resistance at 4200
Yahoo Finance
·
14 tunni eest
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
MarketWatch
·
1 päeva eest
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profiil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Teave üksuse Cordlife Group Ltd kohta
TegevjuhtYiu Pang Fai
Töötajad111
Asutatud2. mai 2001
Peakontorid-
SektorHealth care provider
Veebisaitcordlife.com